Prescription drug consumers confounded by the cost of their medications can get a peek behind the curtain thanks to new Washington University in St. Louis research into the complex “co-opetition” — cooperation and competition — among drug makers in the middleman-controlled US drug supply chain.But, as explained by  Panos Kouvelis, the Emerson Distinguished Professor of Operations and Manufacturing Management at Olin Business School and director of The Boeing Center for Supply Chain Innovation, the system is so complex and opaque, it may be headed for government regulation.